Gary Tilbrook’s Post

We are pleased to announce that LCC is transitioning from a CRO into a hub-and-spoke biotech company. Our focus will be on generating small molecule lead candidate assets against oncology and rare disease targets. On behalf of all the team, we would like to offer our gratitude to everyone who has supported us along our journey. There are too many to name, but thank you to our investors - Deepbridge Capital, Praetura Ventures, and Maven Capital Partners - who have been with us during the last 10 years and are continuing to support us moving forward; the University of Liverpool, our collaborators, our clients, legal teams, past colleagues, and everyone else we have worked with. Read the full announcement on our new website, which was excellently put together by Mal MacKenzie and the team: https://lnkd.in/eint4FTZ

BillionToOne, a pioneering molecular diagnostics company, has announced a successful Series D funding round, raising $130 million. The oversubscribed round was led by Premji Invest, with substantial contributions from new investor Neuberger Berman and existing investors such as Adam Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. This significant influx of capital will be utilized to expand and scale BillionToOne’s prenatal screening and oncology diagnostics businesses. BillionToOne’s cutting-edge technology, Quantitative Counting Templates™ (QCTs™), enables the precise counting of DNA molecules at the single base-pair level. This innovation has allowed the company to develop unique and differentiated tests that push the boundaries of molecular diagnostics. To date, over half a million patients have benefited from BillionToOne’s tests, and the company has seen remarkable growth, achieving an annual recurring revenue of $125 million in just four years. Read more: https://lnkd.in/dB74aWEv

NEW: Chroma Medicine and Nvelop Therapeutics have merged, combining into nChroma Bio. The deal is the latest signal of a volatile genetic medicines field that has leaned into consolidation to survive. ReNAgade Therapeutics and Orna Therapeutics merged together earlier this year, while other startups have flamed out like Tome Biosciences and Resonance Medicine, Inc. My latest for Endpoints News on nChroma — including how the deal started over two startups CEOs getting tacos:

Check out a great network on New Product Planning in Biopharma! Our latest forum discussion was focused on the evolving role NPP plays in driving strategy not only at the program level but also in shaping franchise and corporate strategy through transversal leadership. Through the discussion I was humbled to learn how much the industry has evolved. With accelerated paths to market, biomarkers, companion diagnostics, and increasing demand for health economics outcomes measures, NPP plays an increasingly important strategic role for shaping future success in #drugdevelopment. Huge shout out to Mike Conlon, Alexander Brown and Chad Faulkner for making it such a dynamic and engaging forum. If you’re interested in more forums like this - check out the content below and sign up for future forums! #biotech #newproductplanning #pharma #strategy https://lnkd.in/eTJqQKtg

❗𝗪𝗔𝗥𝗡𝗜𝗡𝗚: 2 Discounted Passes Left for the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁!   Time is running out to be part of the 𝗺𝗼𝘀𝘁 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗲𝘃𝗲𝗻𝘁 𝗶𝗻 𝗺𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. Don't risk falling behind as top experts 𝗰𝗼𝗻𝗳𝗿𝗼𝗻𝘁 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗽𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 and share their 𝘀𝗲𝗰𝗿𝗲𝘁𝘀 𝗼𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀.   𝗚𝗿𝗮𝗯 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 - https://ter.li/ntamqp   Once these 2 passes are gone, so is your chance to stay ahead in this fast-evolving field.   ⏳ 𝗦𝗮𝘃𝗲 $𝟯𝟬𝟬 𝗯𝘆 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼𝗺𝗼𝗿𝗿𝗼𝘄 - https://ter.li/ook4wg   Don't let this opportunity slip away!   #MacrophageDirectedTherapiesSummit

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

#Asceneuron_sa announces $100 million oversubscribed Series C financing! Today we announce that we have successfully secured a Series C financing, led by Novo Holdings with new investment from EQT Group Life Sciences, OrbiMed and SR One Capital Management Capital Management, alongside participation from existing investors M Ventures , Sofinnova Partners, GSK Equities Investment Limited and Johnson & Johnson Innovation JJDC Inc. The funds will be used to advance our lead asset #ASN51, an oral small molecule drug designed to inhibit #OGA into Phase 2 clinical development for the treatment of Alzheimer’s disease. Click here https://lnkd.in/d278vevG to read the press release and discover more about Asceneuron’s groundbreaking clinical pipeline of O-GlcNAcase inhibitors for the treatment of #neurodegenerative diseases. #neurodegeneration #ALS #alzheimers #parkinson #dementia #financing

📢 Funding News: £35 Million Series A Financing 📢 Today, we announce our Series A financing round led by Forbion, alongside our founding investors SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). The funds will be used to advance our small molecule somatic expansion inhibition therapy for Huntington’s disease. Our lead programme, MutSβ inhibitor is expected to enter the clinic in 2026. In connection with the financing, we welcome Rogier Rooswinkel, General Partner at Forbion to the LoQus23 Board of Directors. At LoQus23, we are investigating small molecule drugs that could stop #DNAinstability and slow #neurodegeneration in #HuntingtonsDisease. We look forward to progressing our pipeline with the support of our investors, so make sure you’re following LoQus23 Therapeutics Ltd on LinkedIn to stay up to date. 👉 Visit our new website to read the press release and find out more by using the link in the comments below. #financing #venturecapital #drugdevelopment #UKbiotech

What a year it has been for Commit Biologics!   🚀 In May we officially launched with a €16m seed financing round from leading life sciences investors Bioqube Ventures and Novo Holdings 📺 Our CEO Krishna Polu appeared on Optimum TV to discuss how our BICE technology is used to “supercharge” conventional antibodies to fight cancer and autoimmune diseases 🎉 We celebrated 3 years of Commit Biologics, having been founded on September 1st, 2021 by Nick Stub Laursen, Dennis Pedersen, Mikael B. L. Winkler, and Heidi Gytz Olesen. ⭐ We were recognised as one of 'Europe’s rising biotech stars: 10 start-ups to watch in 2024' by Labiotech.eu 👨💼 We welcomed Mikkel Wandahl Pedersen, as our new Chief Scientific Officer 🥈We placed 2nd in the ‘Seed-Stage Finance Raise of the Year’ category for the LSX European Lifestars Awards - Celebrating Life Science Leaders   All of this and much, much more!   Thank you to our dedicated and hardworking team who have made this possible - here's to a successful 2025!   #ComplementSystem #Antibodies #BiCE

Our new strategic investment fund 66ten (A$66M, ten-year, open-ended) has been established to drive outstanding science towards commercial reality. Since its foundation, the fund has invested in a range of diverse commercial programs. One of them aims at developing a novel therapeutic drug candidate that addresses the genetic cause of Prader-Willi Syndrome. This specific program is based on a discovery by Professor Marnie Blewitt, which led to a therapeutic strategy focused on activating the patients’ own genes to treat the underlying cause of this disease. Nicholas Liau, Venture Principal Scientist, who has previously worked in early-stage drug discovery at Genentech and Denali Therapeutics, oversees this program. https://lnkd.in/gjdaR-B2